<DOC>
	<DOCNO>NCT03010579</DOCNO>
	<brief_summary>This randomized trial evaluate potential benefit erythropoietin treatment anemia patient lymphoma autologous hematopoietic stem cell transplantation .</brief_summary>
	<brief_title>Erythropoietin Treatment Anemia After Autologous Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>Lymphoma patient anemia day +15 post-transplant randomized erythropoietin group control group . Potential benefit erythropoietin evaluatedon day +60 post-transplant .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>confirm lymphoma first autologous hematopoietic stem cell transplantation hemoglobin level le 100 g/L day +15 posttransplant write informed consent give patient his/her guardian minor age . HIV positive Known allergy recombinant human erythropoietin Uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Hematopoietic stem cell transplantation</keyword>
	<keyword>Erythropoietin</keyword>
</DOC>